These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28064216)

  • 41. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Detection and Analysis of EGFR and KRAS Mutations 
in the Patients with Lung Squamous Cell Carcinomas].
    Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Su D; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):621-5. PubMed ID: 26483334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tyrosine kinase domain mutations of
    Vatte C; Al Amri AM; Cyrus C; Chathoth S; Acharya S; Hashim TM; Al Ali Z; Alshreadah ST; Alsayyah A; Al-Ali AK
    Onco Targets Ther; 2017; 10():1527-1533. PubMed ID: 28352186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
    J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
    Hata A; Katakami N; Yoshioka H; Kunimasa K; Fujita S; Kaji R; Notohara K; Imai Y; Tachikawa R; Tomii K; Korogi Y; Iwasaku M; Nishiyama A; Ishida T
    J Thorac Oncol; 2013 Jan; 8(1):89-95. PubMed ID: 23242440
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.
    Fung C; Zhou P; Joyce S; Trent K; Yuan JM; Grandis JR; Weissfeld JL; Romkes M; Weeks DE; Egloff AM
    Cancer Lett; 2015 Feb; 357(2):549-56. PubMed ID: 25511740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
    Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
    Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.
    Sun HB; Ou W; Li Y; Fang Q; Qin J; Zhang L; Wang SY
    Clin Lung Cancer; 2013 Jul; 14(4):376-82. PubMed ID: 23291256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Sheikh Ali MA; Gunduz M; Nagatsuka H; Gunduz E; Cengiz B; Fukushima K; Beder LB; Demircan K; Fujii M; Yamanaka N; Shimizu K; Grenman R; Nagai N
    Cancer Sci; 2008 Aug; 99(8):1589-94. PubMed ID: 18754871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of phosphorylated and truncated EGFR correlates with higher tumor and nodal stage in head and neck cancer.
    Keller J; Shroyer KR; Batajoo SK; Zhao HL; Dong LM; Hayman MJ; Chan EL
    Cancer Invest; 2010 Dec; 28(10):1054-62. PubMed ID: 20873989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tyrosine 1045 codon mutations in exon 27 of EGFR are infrequent in oral squamous cell carcinomas.
    Tushar MD; Ramanathan A
    Asian Pac J Cancer Prev; 2013; 14(7):4279-82. PubMed ID: 23991943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck.
    Lee JW; Soung YH; Kim SY; Nam HK; Park WS; Nam SW; Kim MS; Sun DI; Lee YS; Jang JJ; Lee JY; Yoo NJ; Lee SH
    Clin Cancer Res; 2005 Apr; 11(8):2879-82. PubMed ID: 15837736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of ras oncogene mutations in human squamous cell carcinoma of the head and neck.
    Núñez F; Domínguez O; Coto E; Suárez-Nieto C; Pérez P; López-Larrea C
    Surg Oncol; 1992 Dec; 1(6):405-11. PubMed ID: 1341278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of B-RAF mutations in head and neck squamous cell carcinoma.
    Al Sheikh Ali M; Gunduz M; Gunduz E; Tamamura R; Beder L; Tominaga S; Onoda T; Yamanaka N; Grenman R; Shimizu K; Nagai N; Nagatsuka H
    Folia Biol (Praha); 2008; 54(5):157-61. PubMed ID: 19178815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance.
    Boscolo-Rizzo P; Tirelli G; Polesel J; Sia E; Phillips V; Borsetto D; De Rossi A; Giunco S
    Oral Oncol; 2023 May; 140():106398. PubMed ID: 37075587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sinonasal squamous cell carcinoma and EGFR mutations: a molecular footprint of a benign lesion.
    Sasaki E; Nishikawa D; Hanai N; Hasegawa Y; Yatabe Y
    Histopathology; 2018 Dec; 73(6):953-962. PubMed ID: 30117182
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of EGFR mutations in head and neck squamous cell carcinomas.
    Kaur G; Phogat D; Manu V
    Autops Case Rep; 2021 Apr; 11():e2021251. PubMed ID: 33968826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential molecular prognostic markers in head and neck squamous cell carcinomas.
    Quon H; Liu FF; Cummings BJ
    Head Neck; 2001 Feb; 23(2):147-59. PubMed ID: 11303632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TP53 Y220C Is a Hotspot Mutation in Oropharyngeal Squamous Cell Carcinoma.
    van Kempen PM; Verdam FJ; de Poel E; Braunius WW; de Weger RA; van Es RJ; Grolman W; Willems SM
    Pathobiology; 2015; 82(1):21-27. PubMed ID: 25765855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.